You are here

Funding

CRUK can propel promising research to the next stage by helping scientists access appropriate translational funding and 'in-kind' support. In 2016/17, we leveraged £29m in industry and external grant support for CRUK researchers.

  • CRUK FUNDING

    Our Business Development Managers can provide support for researchers applying for a Cancer Research UK drug discovery project grant.

    Project grant applications in drug discovery are assessed by the Drug Discovery Expert Review Panel (DDERP), a sub-panel of the CRUK Science Committee. The Drug Discovery Expert Review Panel will consider project grant applications that directly develop research for patient benefit, improving the likelihood of research eventually leading to a new preventative, therapeutic or biomarker entity by:

    • Establishing a project plan, which charts a route to developing research findings.
    • Funding of the project plan to achieve specific milestones and endpoints.
    • Management and monitoring of the project by the charity to achieve goals within agreed timescales.

     

    Related links

  • PROJECT DEVELOPMENT FUND

    CRUK believes that rapid access to ‘kick-start’ or bridging funding is sometimes required by projects in order for them to progress to the next stage, where they may attract further substantial funding or partnering interest. Through the Project Development Fund, limited sums can be granted to projects to help bridge this gap.

    In order to qualify, proposals should have a clearly defined end point which is achievable in the short to medium term. Proposals are not restricted by type but must be consistent with CRUK’s vision and purpose.

    For more information, contact your Business Development Manager or email commercial@cancer.org.uk

  • PIONEER FUND

    The CRT Pioneer Fund (CPF) is a £70 million joint initiative initially established by Cancer Research Technology and the European Investment Fund (EIF). CPF's investors are now Syncona and EIF. The fund’s objective is to bridge the investment gap between cancer drug discovery and early development, by taking potential cancer drugs from discovery through to entry into Phase II clinical trials.

    It is managed by Sixth Element Capital.

    The CPF mainly invests directly into projects. Two thirds of the fund is to be invested in projects sourced from Cancer Research UK funded research. The CPF now has a portfolio of 9 investments. For more information please visit www.sixthelementcapital.com, contact your  Business Development Manager or email commercial@cancer.org.uk.

CRUK FUNDING Open

Our Business Development Managers can provide support for researchers applying for a Cancer Research UK drug discovery project grant.

Project grant applications in drug discovery are assessed by the Drug Discovery Expert Review Panel (DDERP), a sub-panel of the CRUK Science Committee. The Drug Discovery Expert Review Panel will consider project grant applications that directly develop research for patient benefit, improving the likelihood of research eventually leading to a new preventative, therapeutic or biomarker entity by:

  • Establishing a project plan, which charts a route to developing research findings.
  • Funding of the project plan to achieve specific milestones and endpoints.
  • Management and monitoring of the project by the charity to achieve goals within agreed timescales.

 

Related links

PROJECT DEVELOPMENT FUND Open

CRUK believes that rapid access to ‘kick-start’ or bridging funding is sometimes required by projects in order for them to progress to the next stage, where they may attract further substantial funding or partnering interest. Through the Project Development Fund, limited sums can be granted to projects to help bridge this gap.

In order to qualify, proposals should have a clearly defined end point which is achievable in the short to medium term. Proposals are not restricted by type but must be consistent with CRUK’s vision and purpose.

For more information, contact your Business Development Manager or email commercial@cancer.org.uk

PIONEER FUND Open

The CRT Pioneer Fund (CPF) is a £70 million joint initiative initially established by Cancer Research Technology and the European Investment Fund (EIF). CPF's investors are now Syncona and EIF. The fund’s objective is to bridge the investment gap between cancer drug discovery and early development, by taking potential cancer drugs from discovery through to entry into Phase II clinical trials.

It is managed by Sixth Element Capital.

The CPF mainly invests directly into projects. Two thirds of the fund is to be invested in projects sourced from Cancer Research UK funded research. The CPF now has a portfolio of 9 investments. For more information please visit www.sixthelementcapital.com, contact your  Business Development Manager or email commercial@cancer.org.uk.

Related links